Acidic protein found in SARCOPLASMIC RETICULUM that binds calcium to the extent of 700-900 nmoles/mg. It plays the role of sequestering calcium transported to the interior of the intracellular vesicle.
A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions.
The protein constituents of muscle, the major ones being ACTINS and MYOSINS. More than a dozen accessory proteins exist including TROPONIN; TROPOMYOSIN; and DYSTROPHIN.
Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS.
A tetrameric calcium release channel in the SARCOPLASMIC RETICULUM membrane of SMOOTH MUSCLE CELLS, acting oppositely to SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES. It is important in skeletal and cardiac excitation-contraction coupling and studied by using RYANODINE. Abnormalities are implicated in CARDIAC ARRHYTHMIAS and MUSCULAR DISEASES.
A multifunctional protein that is found primarily within membrane-bound organelles. In the ENDOPLASMIC RETICULUM it binds to specific N-linked oligosaccharides found on newly-synthesized proteins and functions as a MOLECULAR CHAPERONE that may play a role in PROTEIN FOLDING or retention and degradation of misfolded proteins. In addition calreticulin is a major storage form for CALCIUM and functions as a calcium-signaling molecule that can regulate intracellular calcium HOMEOSTASIS.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
5,5'-Nitrilodibarbituric acid ammonium derivative. Used as an indicator for complexometric titrations.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Cation-transporting proteins that utilize the energy of ATP hydrolysis for the transport of CALCIUM. They differ from CALCIUM CHANNELS which allow calcium to pass through a membrane without the use of energy.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Contractile tissue that produces movement in animals.
Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation.
A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.
Signal transduction mechanisms whereby calcium mobilization (from outside the cell or from intracellular storage pools) to the cytoplasm is triggered by external stimuli. Calcium signals are often seen to propagate as waves, oscillations, spikes, sparks, or puffs. The calcium acts as an intracellular messenger by activating calcium-responsive proteins.
Calcium-transporting ATPases that catalyze the active transport of CALCIUM into the SARCOPLASMIC RETICULUM vesicles from the CYTOPLASM. They are primarily found in MUSCLE CELLS and play a role in the relaxation of MUSCLES.
Unsaturated azacyclopropane compounds that are three-membered heterocycles of a nitrogen and two carbon atoms.
Red dye, pH indicator, and diagnostic aid for determination of renal function. It is used also for studies of the gastrointestinal and other systems.
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins.

Serial changes in sarcoplasmic reticulum gene expression in volume-overloaded cardiac hypertrophy in the rat: effect of an angiotensin II receptor antagonist. (1/309)

This study was designed to clarify whether gene expression in the cardiac sarcoplasmic reticulum [sarcoplasmic reticulum Ca2+-ATPase (SERCA), phospholamban, ryanodine receptor and calsequestrin] changes in accordance with left ventricular functional alterations in the volume-overloaded heart. Further, the effect of the angiotensin II type 1 receptor antagonist, TCV-116, on the expression of these genes was also evaluated. Left ventricular fractional shortening was significantly increased at 7 days, had returned to control levels at 21 days, and had significantly decreased at 35 days after the shunt operation, compared with sham-operated rats. The level of SERCA mRNA was significantly decreased at both 21 days and 35 days after the shunt operation. The levels of ryanodine receptor and phospholamban mRNAs were significantly decreased at 35 days in shunt-operated rats. The decrease in the SERCA mRNA level preceded the development of cardiac dysfunction. The levels of SERCA and ryanodine receptor mRNAs were correlated positively with left ventricular fractional shortening (r=0.73, P<0.0001 and r=0.61, P<0.01 respectively). Attenuation of the decrease in left ventricular fractional shortening occurred on treatment with TCV-116. After the treatment with TCV-116, the levels of SERCA and phospholamban mRNAs were restored to the respective values in sham-operated rats. Ryanodine receptor mRNA levels remained unchanged after treatment with TCV-116. These results indicate that the down-regulation of SERCA and ryanodine receptor mRNA levels may be related to cardiac dysfunction in the volume-overloaded heart. In addition, treatment with an angiotensin II receptor antagonist may restore the altered sarcoplasmic reticulum mRNA levels to control levels, and this may result in attenuation of the functional impairment in the volume-overloaded heart.  (+info)

Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. (2/309)

OBJECTIVES: We investigated the gene expression of calcium-handling genes including L-type calcium channel, sarcoplasmic reticular calcium adenosine triphosphatase (Ca(2+)-ATPase), ryanodine receptor, calsequestrin and phospholamban in human atrial fibrillation. BACKGROUND: Recent studies have demonstrated that atrial electrical remodeling in atrial fibrillation is associated with intracellular calcium overload. However, the changes of calcium-handling proteins remain unclear. METHODS: A total of 34 patients undergoing open heart surgery were included. Atrial tissue was obtained from the right atrial free wall, right atrial appendage, left atrial free wall and left atrial appendage, respectively. The messenger ribonucleic acid (mRNA) amount of the genes was measured by reverse transcription-polymerase chain reaction and normalized to the mRNA levels of glyceraldehyde 3-phosphate dehydrogenase. RESULTS: The mRNA of L-type calcium channel and of Ca(2+)-ATPase was significantly decreased in patients with persistent atrial fibrillation for more than 3 months (0.36+/-0.26 vs. 0.90+/-0.88 for L-type calcium channel; 0.69+/-0.42 vs. 1.21+/-0.68 for Ca(2+)-ATPase; both p < 0.05, all data in arbitrary unit). We further demonstrated that there was no spatial dispersion of the gene expression among the four atrial tissue sampling sites. Age, gender and underlying cardiac disease had no significant effects on the gene expression. In contrast, the mRNA levels of ryanodine receptor, calsequestrin and phospholamban showed no significant change in atrial fibrillation. CONCLUSIONS: L-type calcium channel and the sarcoplasmic reticular Ca(2+)-ATPase gene were down-regulated in atrial fibrillation. These changes may be a consequence of, as well as a contributory factor for, atrial fibrillation.  (+info)

Reduced sodium pump alpha1, alpha3, and beta1-isoform protein levels and Na+,K+-ATPase activity but unchanged Na+-Ca2+ exchanger protein levels in human heart failure. (3/309)

BACKGROUND: Cardiac glycosides initiate an increase in force of contraction by inhibiting the sarcolemmal sodium pump (Na+, K+-ATPase), thereby decreasing Ca2+ extrusion by the Na+-Ca2+ exchanger, which increases the cellular content of Ca2+. In patients with heart failure the sensitivity toward cardiac glycosides is enhanced. METHODS AND RESULTS: Because the inotropic effect of cardiac glycosides may be a function of the sodium pump and Na+-Ca2+ exchanger (NCE) expression levels, the present study aimed to investigate protein expression of both transporters (immunoblot with specific antibodies against the sodium pump catalytic alpha1-, alpha2-, alpha3-, and glycoprotein beta1-isoforms and against NCE) in left ventricle from failing (heart transplantations, New York Heart Association class IV, n=21) compared with nonfailing (donor hearts, NF, n=22) human myocardium. The density of 3H-ouabain-binding sites (Bmax) and the Na+,K+-ATPase activity were also measured. In NYHA class IV, protein levels of Na+,K+-ATPase alpha1- (0.62+/-0.06 of control), alpha3- (0.70+/-0.09), and beta1- (0.61+/-0.04) but not alpha2-isoforms were significantly reduced (P<0.01), whereas levels of NCE (0.92+/-0.13 of control) and calsequestrin (0.98+/-0.06) remained unchanged. Both Na+,K+-ATPase activity (NF: 1.9+/-0.29; NYHA class IV: 1.1+/-0.17 micromol ATP/min per milligram of protein) and the 3H-ouabain binding sites (Bmax NF: 15.9+/-1.9 pmol/mg protein; NYHA class IV: 9.7+/-1.5) were reduced in NYHA class IV and correlated significantly to each other (r2=0. 73; P<0.0001), as did beta1-subunit expression. In left ventricular papillary muscle strips from NYHA class IV compared with nonfailing tissue the Na+-channel modulator BDF 9198 exerted an increase in force of contraction with unchanged effectiveness but enhanced potency. CONCLUSIONS: The enhanced sensitivity of failing human myocardium toward cardiac glycosides may be, at least in part, attributed to a reduced protein expression and activity of the sarcolemmal Na+,K+-ATPase without a change in Na+-Ca2+ exchanger protein expression.  (+info)

Analysis of calsequestrin gene expression using green fluorescent protein in Caenorhabditis elegans. (4/309)

The calsequestrin gene of Caenorhabditis elegans is expressed in body-wall muscle cells during muscle development. In order to study the body-wall muscle specific regulation of the calsequestrin gene expression, approximately 2 kb upstream sequences of the calsequestrin gene were analyzed. Transcriptional fusion constructs utilizing green fluorescent protein as a reporter gene were made and microinjected to produce germ-line transformed transgenic C. elegans. The expression of green fluorescent protein was observed in the body-wall muscles of live transgenic animals under fluorescence microscopy. Deletion analyses of upstream sequences have revealed a putative promoter sequence and a regulatory element which appeared to enhance reporter gene expression. Both sequence elements are juxtaposed to constitute a 260 bp regulatory region approximately 260 bp upstream from the putative translational initiation codon. Several possible binding sites for transcription factors were identified including the sites for YY1 and NF-W2, a muscle specific zinc finger transcription factor, and an ubiquitous enhancer binding protein, respectively. Interestingly, this region also contains a 20 bp sequence element identical to those found in the mouse dystrophin gene, which suggests a possible role of this regulatory region in muscle specific gene regulation.  (+info)

Subunit expression of the cardiac L-type calcium channel is differentially regulated in diastolic heart failure of the cardiac allograft. (5/309)

BACKGROUND: Left ventricular diastolic dysfunction is a major cause of cardiac allograft failure. Multimeric L-type calcium channels (alpha1-, alpha2/delta-, and beta-subunits) are essential for excitation/contraction coupling in the heart. Their gene expression was studied in allografts that developed diastolic heart failure. METHODS AND RESULTS: mRNA levels of calcium channel subunits were measured by competitive reverse transcriptase-polymerase chain reaction in microbiopsy samples from the interventricular septum. Size and tissue variabilities between biopsy samples were assessed by determination of cardiac calsequestrin mRNA levels. In the cardiac allografts studied, mRNA levels in microbiopsy samples were considered to represent left ventricular gene expression, because septal and left ventricular gene expression in Northern blots was equivalent, and left ventricles contracted homogeneously. Biopsy samples (n=72) were taken from allografts with normal left ventricular end-diastolic pressure (LVEDP; 8 to 13 mm Hg; n=30), moderately elevated LVEDP (14 to 18 mm Hg; n=26), and elevated LVEDP (19 to 28 mm Hg; n=16). Increased LVEDP was related to slowed diastolic relaxation determined by the time constant tau (r2=0.86), whereas systolic performance (dP/dt; ejection fraction) was preserved. With increasing LVEDP, mRNA levels of the pore-forming alpha1c-subunit (n=15) and of the regulatory alpha2/delta-subunit (n=17) remained unchanged but decreased exponentially (r2=-0.83) for the regulatory beta-subunit (n=40). Compared with cardiac allografts with normal LVEDP (n=15), beta-subunit mRNA level was reduced by 75% at elevated LVEDP (n=9; P=0.012). In an explanted, diastolically failing cardiac allograft, beta-subunit expression was reduced correspondingly by 72% and 76% on the mRNA level in septal and left ventricular myocardium and by 80% on the protein level. CONCLUSIONS: The downregulated expression of the calcium channel beta-subunit might contribute to altered calcium handling in diastolically failing cardiac allografts.  (+info)

Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. (6/309)

Calsequestrin is a high capacity Ca(2+)-binding protein in the junctional sarcoplasmic reticulum that forms a quaternary complex with junctin, triadin, and the ryanodine receptor. Transgenic mice with cardiac-targeted calsequestrin overexpression show marked suppression of Ca(2+)-induced Ca(2+) release, myocyte hypertrophy, and premature death by 16 weeks of age (Jones, L. R., Suzuki, Y. J., Wang, W., Kobayashi, Y. M., Ramesh, V., Franzini-Armstrong, C., Cleemann, L., and Morad, M. (1998) J. Clin. Invest. 101, 1385-1393). To investigate whether alterations in intracellular Ca(2+) trigger changes in the beta-adrenergic receptor pathway, we studied calsequestrin overexpressing transgenic mice at 7 and 14 weeks of age. As assessed by echocardiography, calsequestrin mice at 7 weeks showed mild left ventricular enlargement, mild decreased fractional shortening with increased wall thickness. By 14 weeks, the phenotype progressed to marked left ventricular enlargement and severely depressed systolic function. Cardiac catheterization in calsequestrin mice revealed markedly impaired beta-adrenergic receptor responsiveness in both 7- and 14- week mice. Biochemical analysis in 7- and 14-week mice showed a significant decrease in total beta-adrenergic receptor density, adenylyl cyclase activity, and the percent high affinity agonist binding, which was associated with increased beta-adrenergic receptor kinase 1 levels. Taken together, these data indicate that alterations in beta-adrenergic receptor signaling precede the development of overt heart failure in this mouse model of progressive cardiomyopathy.  (+info)

Characterization of the binding and phosphorylation of cardiac calsequestrin by epsilon protein kinase C. (7/309)

In this study, we report the cloning of the rat cardiac isoform of calsequestrin on the basis of its interaction with an epsilonprotein kinase C-unique sequence (epsilonV1) derived form the epsilonprotein kinase C regulatory domain. Calsequestrin binds activated epsilonprotein kinase C holoenzyme better than the inactive enzyme and nearly three times better than other protein kinase C isozymes. The interaction between epsilonprotein kinase C and calsequestrin is mediated by sequences in both the regulatory and kinase domains of the epsilonprotein kinase C. Finally, we show that calsequestrin is an epsilonprotein kinase C substrate in vitro and protein kinase C phosphorylation of calsequestrin leads to a decreased binding of epsilonprotein kinase C to calsequestrin.  (+info)

Heterogeneous transmural gene expression of calcium-handling proteins and natriuretic peptides in the failing human heart. (8/309)

OBJECTIVE: Human heart failure is associated with a disturbed intracellular calcium (Ca2+) homeostasis. In this regard, ventricular wall stress is considered to be a determinant for expression of sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a). In the present study, we analyzed the transmural protein and/or mRNA levels of SERCA2a, other Ca(2+)-handling proteins, and of atrial and brain natriuretic peptides (ANP and BNP) in the human heart. METHODS: Subepicardial (epi), midmyocardial (mid), and subendocardial (endo) sections of the left ventricular free wall from end-stage failing (n = 17) and nonfailing (n = 5) human hearts were analyzed by Western blot for immunoreactive protein levels of SERCA2a, phospholamban (PLN), and calsequestrin (CS). Subepi- and subendocardial sections were analyzed by Northern blot for steady-state mRNA levels of SERCA2a, Na(+)-Ca2+ exchanger (NCX1), ANP, and BNP. RESULTS: SERCA2a protein and mRNA levels were reduced by 40 +/- 5% (P < 0.01) and 25 +/- 7% (P < 0.05) in endo compared to epi in the failing heart and by 27 +/- 14% and 16 +/- 12% (non-significant) in the nonfailing heart, respectively. PLN protein levels were reduced by 23 +/- 6% (P < 0.05) in endo compared to epi in the failing heart and by 17 +/- 25% (non-significant) in the nonfailing heart, whereas CS protein levels and NCX1 mRNA levels were similar across the left ventricular wall. Strikingly, in the failing heart, both BNP and ANP mRNA levels were upregulated predominantly in endo. CONCLUSIONS: In the failing human heart, SERCA2a and PLN, as well as natriuretic peptides but not CS and NCX1 are differentially expressed across the left ventricular wall, implicating (1) different susceptibility of subendocardium and subepicardium to factors affecting expression of these proteins and (2) differences in regulation of the distinct calcium-cycling proteins.  (+info)

Tachycardia, ventricular can be classified into several types based on its duration and the presence of other symptoms. These include:

1. Paroxysmal ventricular tachycardia (PVT): This is a rapid heart rate that occurs in episodes lasting less than 30 seconds and may be accompanied by palpitations, shortness of breath, or dizziness.
2. Sustained ventricular tachycardia: This is a rapid heart rate that persists for more than 30 seconds and may require medical intervention to return the heart to normal rhythm.
3. Ventricular fibrillation (VF): This is a life-threatening condition in which the ventricles are unable to pump blood effectively due to rapid, disorganized electrical activity.

Symptoms of tachycardia, ventricular may include:

* Palpitations or rapid heartbeat
* Shortness of breath
* Dizziness or lightheadedness
* Chest pain or discomfort
* Fatigue or weakness

Diagnosis of tachycardia, ventricular is typically made based on a physical examination, medical history, and results of diagnostic tests such as electrocardiogram (ECG), echocardiogram, or stress test. Treatment options may include medications to regulate heart rhythm, cardioversion to restore normal heart rhythm, and in some cases, implantation of a cardioverter-defibrillator (ICD) to prevent sudden death.

In summary, tachycardia, ventricular is a rapid heart rate that originates in the ventricles and can be caused by a variety of conditions. It is important to seek medical attention if symptoms persist or worsen over time. With proper diagnosis and treatment, it is possible to manage the condition and improve quality of life.

Types of Immunoproliferative Disorders:

1. Lymphoproliferative Disorders: These are characterized by the excessive proliferation of lymphocytes, a type of immune cell. Examples include lymphoma, Hodgkin's disease, and non-Hodgkin's lymphoma.
2. Myeloproliferative Disorders: These are characterized by the excessive proliferation of myeloid cells, such as white blood cells, red blood cells, and platelets. Examples include polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
3. Autoimmune Disorders: These are characterized by the immune system attacking the body's own tissues. Examples include rheumatoid arthritis, lupus, and multiple sclerosis.

Causes and Risk Factors:

Immunoproliferative disorders can be caused by a variety of factors, including genetic mutations, infections, and exposure to certain chemicals or toxins. Some risk factors for immunoproliferative disorders include:

1. Genetic predisposition
2. Exposure to certain viruses, such as human T-lymphotropic virus (HTLV) and Epstein-Barr virus (EBV)
3. Exposure to certain chemicals or toxins, such as benzene and certain pesticides
4. Weakened immune system due to disease or medication
5. Age, with older adults being more susceptible to certain types of immunoproliferative disorders

Symptoms:

The symptoms of immunoproliferative disorders can vary depending on the specific type and severity of the condition. Some common symptoms include:

1. Swollen lymph nodes
2. Fever
3. Fatigue
4. Weight loss
5. Night sweats
6. Skin rashes or lesions
7. Joint pain or swelling
8. Muscle weakness
9. Nervous system problems, such as numbness or tingling in the hands and feet
10. Swollen spleen

Treatment:

The treatment of immunoproliferative disorders depends on the specific type and severity of the condition. Some common treatments include:

1. Medications to suppress the immune system, such as corticosteroids and immunosuppressive drugs
2. Antiviral medications to treat infections that may be contributing to the condition
3. Chemotherapy to reduce the number of abnormal cells in the body
4. Radiation therapy to reduce the size of swollen lymph nodes or other affected tissues
5. Plasmapheresis, a process that removes abnormal antibodies from the blood
6. Bone marrow transplantation, which may be considered for some patients with severe forms of the condition.

Prognosis:

The prognosis for immunoproliferative disorders varies depending on the specific type and severity of the condition. In general, the prognosis is good for patients who receive prompt and appropriate treatment, and who have a mild form of the condition. However, the prognosis is poorer for patients with severe or aggressive forms of the condition, and those who do not respond well to treatment.

Prevention:

There is currently no known way to prevent immunoproliferative disorders. However, early detection and treatment can help improve outcomes. Regular follow-up with a healthcare provider is important for patients with risk factors or symptoms of these conditions.

Two forms of calsequestrin have been identified. The cardiac form Calsequestrin-2 (CASQ2) is present in cardiac and slow ... Calsequestrin is also secreted in the gut where it deprives bacteria of calcium ions.[citation needed]. Cardiac calsequestrin ( ... Each molecule of calsequestrin can bind 18 to 50 Ca2+ ions. Sequence analysis has suggested that calcium is not bound in ... Calsequestrin is a calcium-binding protein that acts as a calcium buffer within the sarcoplasmic reticulum. The protein helps ...
Calbindin Calmodulin Calsequestrin Kinjo, Tashi G; Schnetkamp, Paul PM. Ca2+ Chemistry, Storage and Transport in Biologic ... low-affinity calcium-binding protein calsequestrin. Calretinin is another type of Calcium binding protein weighing 29kD. It is ...
This gene encodes calsequestrin, the major calcium-binding protein and calcium buffer within the sarcoplasmic reticulum. ... The calcium is then held within the sarcoplasmic reticulum by a protein called calsequestrin. Fine-tuning of this process can ... Mutations associated with CPVT have also been identified in the CASQ2 gene which encodes calsequestrin, a protein that binds ... In addition to its role as a calcium buffer, calsequestrin also regulates the release of calcium from the sarcoplasmic ...
... as more is bound to calsequestrin). Therefore, more calcium can be stored (the calsequestrin is said to be a buffer). It is ... However, if calcium within the SR rises too high, more calcium binds to the calsequestrin and therefore it binds to the junctin ... Located within the SR is a protein called calsequestrin. This protein can bind to around 50 Ca2+, which decreases the amount of ... If calcium concentration within the SR falls too low, there will be less calcium bound to the calsequestrin. This means that ...
... calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane". The Journal of ...
Shin, D. W.; Ma, J.; Kim, D. H. (2000). "The asp-rich region at the carboxyl-terminus of calsequestrin binds to Ca2+ and ... Shin DW, Ma J, Kim DH (2001). "The asp-rich region at the carboxyl-terminus of calsequestrin binds to Ca2+ and interacts with ... Guo, W; Campbell K P (Apr 1995). "Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the ... Gyorke, I.; Hester, N.; Jones, L. R.; Gyorke, S. (2004). "The Role of Calsequestrin, Triadin, and Junctin in Conferring Cardiac ...
Movsesian MA, Karimi M, Green K, Jones LR (August 1994). "Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels ...
Guo W, Campbell KP (April 1995). "Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the ...
... rescue of the calsequestrin overexpression model of cardiomyopathy". American Journal of Physiology. Heart and Circulatory ...
"Sarcoplasmic-endoplasmic-reticulum Ca2+-ATPase and calsequestrin are overexpressed in spared intrinsic laryngeal muscles of ...
Calsequestrin has multiple Ca2+ binding sites and binds Ca2+ ions with very low affinity so they can be easily released. ... The cardiac-specific isoform of the receptor (RyR2) is known to form a quaternary complex with luminal calsequestrin, junctin, ...
... sarcoplasmic reticulum has a large calcium buffering capacity partially due to a calcium-binding protein called calsequestrin. ...
... sarcoplasmic reticulum has a large calcium buffering capacity partially due to a calcium-binding protein called calsequestrin. ...
Genetic mutations affecting calsequestrin are responsible for an autosomal recessive form of catecholaminergic polymorphic ... while the most important within calcium buffer within the sarcoplasmic reticulum is calsequestrin. Alterations in calcium ...
This is thought to be due to the calsequestrin binding more strongly to the RyR, preventing it from opening and decreasing the ... As well as this, a protein called calsequestrin (found within the SR) detaches from the RyR, when calcium concentration is too ...
... also known as calregulin, CRP55, CaBP3, calsequestrin-like protein, and endoplasmic reticulum resident protein 60 ...
Another protein, calsequestrin, binds calcium within the SR and helps to reduce the concentration of free calcium within the SR ...
... calsequestrin, and RYR1 have been shown to bind to cylindrical spirals. Cylindrical spirals have also been shown to react with ...
Hearts of calsequestrin-mutant mice expressed more α1-adrenergic receptor than did wild type control mice (P < .05). CONCLUSION ... Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.. Kurtzwald-Josefson, Efrat; Hochhauser, Edith; Bogachenko ... optimize the arrhythmia therapy by pharmacological inhibition of the sympathetic nervous system in the homozygous calsequestrin ...
The CASQ2 gene provides instructions for making a protein called calsequestrin 2. Learn about this gene and related health ... in the calsequestrin 2 protein, while other mutations prevent the cell from producing any functional calsequestrin 2. Studies ... Within myocytes, calsequestrin 2 is located in a cell structure called the sarcoplasmic reticulum, which acts as a storage ... The CASQ2 gene provides instructions for making a protein called calsequestrin 2. This protein is found in heart (cardiac) ...
They contain calsequestrin, heat shock proteins, SR ATPase, and SR calcium-pump proteins. Tubular aggregates also commonly ... and calsequestrin. Ordered two-dimensional arrays are formed at the junctional terminal cisternae, in which each of the 4 ...
Understand the role of cardiac calsequestrin in normal heart development and function. Genomic imprinting is an unusual form of ... Casq2 encodes cardiac calsequestrin, a protein that regulates opening of the RyR Ca2+ channel in cardomyocyte junctional ... Understand the role of cardiac calsequestrin in normal heart development and function. ...
Antibodies for proteins involved in skeletal muscle tissue development pathways, according to their Panther/Gene Ontology Classification
Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. Faggioni M, Savio- ...
Calsequestrin Preferred Term Term UI T006171. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1976). ... Calsequestrin Preferred Concept UI. M0003229. Registry Number. 0. Scope Note. Acidic protein found in SARCOPLASMIC RETICULUM ... Calsequestrin. Tree Number(s). D12.776.157.125.155. D12.776.210.500.220. Unique ID. D002155. RDF Unique Identifier. http://id. ...
Effect of calsequestrin type 1 knockout (CASQ1-null) on total releasable Ca2+ store content.. A) Representative fura-FF ratio ...
Although studies suggest that the jSR protein triadin anchors cardiac calsequestrin (Casq2) to RyR2, its contribution to E-C ...
Calsequestrin Preferred Term Term UI T006171. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1976). ... Calsequestrin Preferred Concept UI. M0003229. Registry Number. 0. Scope Note. Acidic protein found in SARCOPLASMIC RETICULUM ... Calsequestrin. Tree Number(s). D12.776.157.125.155. D12.776.210.500.220. Unique ID. D002155. RDF Unique Identifier. http://id. ...
... calsequestrin 1,gngm ppp1r14a,ppp1r14a,C1423014,17-kda pkc-potentiated inhibitory protein of pp1,gngm muscular branch of left ... calsequestrin, fast-twitch, cardiac muscle,gngm right retromandibular vein,right retromandibular vein,C0923969,right ...
Calsequestrin - Preferred Concept UI. M0003229. Scope note. Acidic protein found in SARCOPLASMIC RETICULUM that binds calcium ...
In the paper described here, Thomas Hund and Yoram Rudy present a detailed, and physiologically realistic, mathematical model of a canine ventricular cell. Model simulations are able to recreate the rate-dependent phenomena associated with ion-channel kinetics, action potential properties, and calcium ion handling. The model is based on an epicardial myocyte because these cells contain the largest transient outward potassium current (when compared with endocardial or midmyocardial myocytes). The calcium/calmodulin-dependent protein kinase (CaMKII) regulatory pathway was embedded within the electrophysiological model, incorporating calcium-release formulation, calcium subspace, and dynamic chloride handling. Results from the model simulations revealed CaMKII is an important determinant of the rate dependence of the calcium transient, but not of the action potential duration, which depends instead on the ion-channel kinetics. * Original CellML note: * This CellML version of the model has been ...
The protein encoded by this gene specifies the cardiac muscle family member of the calsequestrin family. Calsequestrin is ... Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in ... The protein encoded by this gene specifies the cardiac muscle family member of the calsequestrin family. Calsequestrin is ... Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in ...
A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations. De La Fuente, S., Van ...
Most mutations that have been linked to CPVT are found in two genes, i.e., ryanodine receptor 2 (RyR2) and calsequestrin 2 ( ...
DeCS 2008 - March 17, 2008 version. ...
C192753 O14958 Calsequestrin-2 C38908 P31358 CAMPATH-1 Antigen C38410 P17612 cAMP-Dependent Protein Kinase Catalytic Subunit ...
Calmodulin-Binding Proteins N0000170609 Calnexin N0000167570 Calpain N0000170616 Calreticulin N0000169592 Calsequestrin ...
Membrane and intracellular systems (L-type calcium channels, ryanodine receptor, calsequestrin) regulate the supply of calcium ...
Calsequestrin 2. PR27280. 25 ug. Calsequestrin 2. PR27280. 5 ug. Neurogranin. PR27174. 10 ug. ...
... calsequestrin and Homer. Information is evolving in terms of understanding both the physical/molecular nature of the protein- ...
... calsequestrin Cs,carcino-sarcoma Cs,carcinosarcoma Cs,cardiac sarcoidosis Cs,cardiogenic shock Cs,cardioplegic solution Cs, ...
A4.411.125 Calsequestrin D12.776.157.125.155 Cancer Vaccines D12.776.828.868.200 D24.310.894.865.200 D24.611.216.865.200 ...
Calsequestrin [D12.776.210.500.220] Calsequestrin * CapZ Actin Capping Protein [D12.776.210.500.227] ...
This graph shows the total number of publications written about "Tropomodulin" by people in this website by year, and whether "Tropomodulin" was a major or minor topic of these publications ...
Phylogenetic and biochemical analysis of calsequestrin structure and association of its variants with cardiac disorders ...
Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin ... Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin ...
  • Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. (medlineplus.gov)
  • Membrane and intracellular systems (L-type calcium channels, ryanodine receptor, calsequestrin) regulate the supply of calcium to contractile proteins throughout contraction. (lookupdesign.net)
  • Within myocytes, calsequestrin 2 is located in a cell structure called the sarcoplasmic reticulum, which acts as a storage center for calcium ions. (medlineplus.gov)
  • In response to certain signals, calcium ions stored by calsequestrin 2 in the sarcoplasmic reticulum are released into the surrounding cell fluid (the cytoplasm). (medlineplus.gov)
  • A lack of properly functioning calsequestrin 2 may also affect regulation of the RYR2 channel, allowing calcium ions to "leak" out of the sarcoplasmic reticulum. (medlineplus.gov)
  • To optimize the arrhythmia therapy by pharmacological inhibition of the sympathetic nervous system in the homozygous calsequestrin knockout (CASQ2(Δ/Δ)) mouse model of CPVT2. (bvsalud.org)
  • The CASQ2 gene provides instructions for making a protein called calsequestrin 2. (medlineplus.gov)
  • Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. (bvsalud.org)
  • Calsequestrin is the major Ca 2+ binding protein in the sarcoplasmic reticulum (SR), serves as the main Ca 2+ storage and buffering protein and is an important regulator of Ca 2+ release channels in both skeletal and cardiac muscle. (nih.gov)
  • Recent studies reveal new insights on calsequestrin trafficking, Ca 2+ binding, protein evolution, protein-protein interactions, stress responses and the molecular basis of related human muscle disease, including catecholaminergic polymorphic ventricular tachycardia (CPVT). (nih.gov)
  • Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. (nih.gov)
  • Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. (medlineplus.gov)
  • The protein encoded by this gene specifies the cardiac muscle family member of the calsequestrin family. (nih.gov)
  • Understand the role of cardiac calsequestrin in normal heart development and function. (nih.gov)